Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular - Takeaways - MDSpire

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

  • By

  • Steven E. Nissen

  • Kathy Wolski

  • David D’Alessio

  • Govinda Weerakkody

  • Jacek Kiljanski

  • Russell J. Wiese

  • Imre Pavo

  • Bertrand Cariou

  • Stephen J. Nicholls

  • June 1, 2026

  • 0 min

Share

  • 1

    Incretin-based therapies, including GLP-1 receptor agonists, are important for managing type 2 diabetes and associated cardiovascular conditions.

  • 2

    Tirzepatide, introduced in 2022, is a dual agonist that targets GLP-1 and GIP receptors, showing benefits over traditional GLP-1 agonists.

  • 3

    The SURPASS-CVOT trial demonstrated that tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events.

  • 4

    The current analysis evaluated a 6-component composite cardiorenal end point, expanding beyond the original 3-component focus.

  • 5

    The trial enrolled patients aged 40 and older with type 2 diabetes and established atherosclerotic cardiovascular disease.

Original Source(s)

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

  • by Steven E. Nissen, Kathy Wolski, David D’Alessio, Govinda Weerakkody, Jacek Kiljanski, Russell J. Wiese, Imre Pavo, Bertrand Cariou, Stephen J. Nicholls

  • June 1, 2026

Related Content

Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations

Rethinking Sudden Death in Heart Failure With Mildly Reduced or Preserved Ejection Fraction